AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, smarter path to launch.

The stock is coming off a strong year.

Whisper it, but we may finally be seeing the IPO window reopening in 2026. | Whisper it, but we may finally be seeing the IPO window reopening in 2026.

Over the past two calendar years, acquirers have agreed to pay more than $38 billion to purchase venture-backed companies in ...

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

Unnatural Products is proving to be a natural at securing partnerships, this time linking up with Novartis in a deal that could garner up to $1.7 billion in biobucks.

NG Biotech manufactured the assays in France, with Hardy Diagnostics serving as the exclusive distributor in the US.

Aerska, a startup developing treatments to silence the problematic genes that cause various brain diseases, has raised $39 ...

Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...

We take a look at Oxford’s biotech and life sciences hub to discover what makes this historical city a hotspot for scientific ...